CytoDyn (CYDY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2024 Annual Meeting will be held virtually on November 22, 2024, with voting eligibility for shareholders of record as of September 30, 2024.
Key proposals include electing five directors, ratifying the appointment of Marcum LLP as auditor, and an advisory vote on executive compensation.
The Board recommends voting in favor of all proposals and nominees.
Voting matters and shareholder proposals
Shareholders will vote on electing five directors, ratifying Marcum LLP as auditor, and approving executive compensation on an advisory basis.
The Board recommends voting “FOR” all nominees and proposals.
Shareholders can vote online, by phone, or by mail, and may revoke proxies before the meeting.
Proposals 1 and 3 are expected to be non-routine, requiring explicit voting instructions from brokers.
Shareholder proposals for the 2025 meeting must be submitted between July 25 and August 25, 2025.
Board of directors and corporate governance
The Board consists of five independent directors, all nominated for re-election.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with independent members.
The Board is chaired by an independent director, with a policy of director attendance at annual meetings.
The Nominating Committee considers diversity and ethical behavior in director selection.
An anti-hedging policy prohibits directors and employees from engaging in certain stock transactions.
Latest events from CytoDyn
- Promising phase II data and rapid enrollment highlight strong momentum for leronlimab in oncology.CYDY
16th Annual LD Micro Invitational Conference - Leronlimab shows robust ctDNA declines and tumor control in advanced colorectal cancer.CYDY
Study update - Clinical-stage biotech registers 278M shares for resale; future hinges on leronlimab and new funding.CYDY
Registration filing - Quarterly net loss of $4.7M, major notes extended, and ongoing going concern risk persists.CYDY
Q3 2026 - Net loss of $22.6 million and legal settlement accrual raise going concern risks.CYDY
Q2 2026 - Up to 120M shares may be sold for $30M to fund oncology trials, with notable dilution risk.CYDY
Registration Filing - Biotech aims to raise $100M for oncology drug development, facing high financial and regulatory risk.CYDY
Registration Filing - Shareholders will vote on director elections, auditor ratification, executive pay, and a share increase.CYDY
Proxy Filing - All director nominees and proposals were preliminarily approved at the 2024 annual meeting.CYDY
AGM 2024